Periodic Reporting for period 1 - BQ-Technology (BrainQ, non-invasive, very low intensity, BCI-based frequency dependent electromagnetic field tailored treatment for neuro recovery (BQ).)
Período documentado: 2018-08-01 hasta 2018-11-30
BrainQ is on a mission to revolutionise how we treat and manage neurological disorders such as stroke and spinal cord injury (SCI) through Artificial Intelligence (AI).
In the EU alone, the total cost of stroke to healthcare providers in 2015 was €45 Billion , with 72% of this being for direct in-hospital care based on data provided by SAFE (Stroke Alliance for Europe) . SCI, on the other hand, has lower incidence rates however still generates a substantial economic burden.
The overall onbjectives of BrainQ are related to the development and clinical validation of the innovative device, the BQ 1.0. The Phase 1 projects objectives are related to the technical and busienss feasibility assessment of the project.
In the EU alone, the total cost of stroke to healthcare providers in 2015 was €45 Billion , with 72% of this being for direct in-hospital care based on data provided by SAFE (Stroke Alliance for Europe) . SCI, on the other hand, has lower incidence rates however still generates a substantial economic burden.
The overall onbjectives of BrainQ are related to the development and clinical validation of the innovative device, the BQ 1.0. The Phase 1 projects objectives are related to the technical and busienss feasibility assessment of the project.
During the project, BrainQ reviewed the current stage of development and updated the development plan for the BQ 1.0. Within the duration of the project, the Company has also engaged with leading research hospitals in Italy and Spain. Discussions with these key stake holders have helped BrainQ palnning the clinical validation work foreseen in Europe.
The Company improved their understanding of the EU market and of the regulations affecting the commercialsiation of the BQ 1.0 in Europe.
The Company improved their understanding of the EU market and of the regulations affecting the commercialsiation of the BQ 1.0 in Europe.
The BQ 1.0 is an innovative Brain Computer Interface (BCI) - based device that provides a completely non-invasive treatment for a broad range of neurological conditions such as stroke, spinal cord injury (SCI), and traumatic brain injury (TBI). The development of the BQ 1.0 has brought BrainQ to create a large-scale data set of EEG motor tasks currently composed of over 100,000 motor tasks files. The device delivers an electromagnetic treatment that is expected to enhance motor function and overall rehabilitation outputs for thousands of patients suffering from neuro trauma with motor impairment.